{
  "docId": "019de070-3657-744f-8469-a4294fbedcbe",
  "docSlug": "17e3f38e05c3dcb59be9aebb9723e39c",
  "documentTitle": "Relay Therapeutics | IPO Presentation Deck | 25 slides",
  "authorId": "relay-therapeutics",
  "authorName": "Relay Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 25,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes preclinical data comparing RLY-4008 to Pemigatinib, Infigratinib, and TAS-120.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3657-744f-8469-a4294fbedcbe/14",
  "deckHref": "/decks/019de070-3657-744f-8469-a4294fbedcbe",
  "deckJsonHref": "/decks/019de070-3657-744f-8469-a4294fbedcbe.json",
  "deckAnchorHref": "/decks/019de070-3657-744f-8469-a4294fbedcbe#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.36,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Complete regression observed in vivo",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04502386-f1d1-4dbb-841f-b1239667515e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.68,
        "y": 0.18
      },
      "kind": "callout",
      "text": "No hyperphosphatemia observed preclinically",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7c4b6e1-8677-42d9-b9ec-ba6ba0a4b270",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Relay Tx compound is highly selective for FGFR2 over FGFR1",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df7b9e62-da5e-4218-83a6-f09e8185f257",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Fold selectivity FGFR2 over FGFR1",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da01e68a-12cb-4a12-be89-4dde9b8d20cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.68,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Serum Phosphate (mM)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9acc1989-10f7-407e-8f1b-14f7980633f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.36,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Tumor Volume (mm3)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e0d2a63-e6df-4bf7-a3be-89b962f848ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "In addition to FGFR2 selectivity, RLY-4008 retains activity against the most frequently reported resistance mutations (including the Gatekeeper Mutations and N550K)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87c7576f-29e6-4543-9e47-feb4b44c05db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Note: Selectivity chart above shows biochemical selectivity. Cellular assay also shows >200 fold FGFR2 selectivity over FGFR1 for RLY-4008. * FGFR2-fusion Intrahepatic cholangiocarcinoma ICC PDX Model",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa9ced7c-eb06-43e1-8b3f-5de0dc5d37c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "FGFR2 – Selectivity and Potency Observed with RLY-4008",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8379864e-753b-45d0-b524-63f405d3ba14",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}